E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
pt with surgically resected pancreatic cancer |
|
E.1.1.1 | Medical condition in easily understood language |
pt with surgically resected pancreatic cancer |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Cancer [C04] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 19.0 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10033604 |
E.1.2 | Term | Pancreatic cancer |
E.1.2 | System Organ Class | 100000004864 |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
Disease-free survival (DFS), defined as the time from the date of randomization to the date of disease recurrence determined by investigator assessment of objective radiographic disease assessments per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1, or death, whichever is earlier. |
|
E.2.2 | Secondary objectives of the trial |
1) Overall survival (OS), which is defined as the time from the date of randomization to the date of death of any cause
2) Safety (Data on safety parameters) and tolerability of the treatment regimens assessed by a summary of adverse events and clinical laboratory assessments
3) Quality of life (QoL)
Exploratory
1) Determination of plasma YKL-40 and IL-6 and circulating tumor KRAS mutations in plasma and urine
|
|
E.2.3 | Trial contains a sub-study | Yes |
E.2.3.1 | Full title, date and version of each sub-study and their related objectives |
Correlation between biomarkers in blood (e.g. Ca-19-9, IL-6, CRP and YKL- 40) and clinical endpoints. |
|
E.3 | Principal inclusion criteria |
1. Signed informed consent
2. Histologically confirmed resected ductal pancreatic adenocarcinoma with macroscopic complete resection (R0 and R1). Subjects with neuroendocrine (and mixed type) tumors are excluded
3. Subject should be able to start treatment no later than 12 weeks postsurgery
4. Male or non-pregnant, non-lactating females who are ≥18 years of age at the time of signing the informed consent form (ICF)
5. ECOG/WHO Performance Status (PS) 0-1
6. Females of child-bearing potential (defined as a sexually mature woman who (1) has not undergone hysterectomy [the surgical removal of the uterus] or bilateral oophorectomy [the surgical removal of both ovaries] or (2) has not been naturally postmenopausal for at least 24 consecutive months [i.e., has had menses at any time during the preceding 24 consecutive months]) must:
• Agree to the use of two physician-approved contraceptive methods (oral, injectable, or implantable hormonal contraceptive; tubal ligation; intra-uterine device; barrier contraceptive with spermicide; or vasectomized partner) while on study IP; and for 3months following the last dose of IP
• Has negative serum pregnancy test (β-hCG) result at screening
7. Male subjects:
• Must practice true abstinence or agree to use a condom during sexual contact with a pregnant female or a female of childbearing potential while participating in the study, during dose interruptions and for 6 months following IP discontinuation, even if he has undergone a successful vasectomy
8. Understand and voluntarily sign an ICF prior to any study related assessments or procedures being conducted
9. Be able to adhere to the study visit schedule and other protocol requirements
10. Acceptable hematology parameters defined as:
• Absolute neutrophil count (ANC) ≥ 1.5 x 10⁹/L
• Platelet count ≥ 100 x 10⁹/L
• Haemoglobin ≥ 5.6 mmol/L
11. Acceptable liver function defined as:
• Serum bilirubin < 1.5 x upper limit of normal (ULN)
• ASAT/ALAT < 2.5 x ULN
12. Acceptable renal function with a creatinine clearance ≥ 50 mL/min/ (e.g., using the Cockroft-Gault formula)
|
|
E.4 | Principal exclusion criteria |
1. Prior neo-adjuvant treatment, radiation therapy, or systemic therapy for pancreatic adenocarcinoma
2. Presence of or history of metastatic or locally recurrent pancreatic adenocarcinoma
3. Other malignancies, except adequately treated basal carcinoma or squamous cell carcinoma of the skin or in situ cervix carcinoma or incidental prostate cancer (T1a, Gleason score ≤ 6, PSA < 0.5 ng/ml), or any other tumor with a DSF survival of ≥ 5 years
4. History of serious or concurrent illness or uncontrolled medical disorder; any medical condition that might be aggravated by chemotherapy treatment or which could not be controlled; including, but not restricted to:
• Active infection requiring antibiotics within 2 weeks before the study inclusion
• Concurrent congestive heart failure NYHA class III - IV
• Unstable angina pectoris, or myocardial infarction within 6 months and/or prior poorly controlled hypertension
• History of interstitial lung disease, slowly progressive dyspnea and unproductive cough, sarcoidosis, silicosis, idiopathic pulmonary fibrosis, pulmonary hypersensitivity pneumonitis or multiple allergies
• Concomitant use of immunosuppressive or myelosuppressive medications that would in the opinion of the investigator, increase the risk of serious neutropenic complications
5. Known or suspected allergy to the investigational agents or any agents given in association with this trial
6. Any psychological, familial, sociological, or geographical condition which does not permit protocol compliance and medical follow-up
7. Enrollment in any other clinical protocol or investigational study with an interventional agent or assessments that may interfere with study procedures
8. Any condition including the presence of laboratory abnormalities, which places the subject at unacceptable risk if he/she were to participate in the study
9. Any condition that confounds the ability to interpret data from the study
10. Unwillingness or inability to comply with study procedures
11. Current use of anticoagulation therapy such as heparins both unfractionated and low molecular weighted
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
Disease-free survival (DFS), defined as the time from the date of randomization to the date of disease recurrence determined by investigator assessment of objective radiographic disease assessments per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1, or death, whichever is earlier. |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
12 month after last patient were included in the trial |
|
E.5.2 | Secondary end point(s) |
) Overall survival (OS), which is defined as the time from the date of randomization to the date of death of any cause
2) Safety (Data on safety parameters) and tolerability of the treatment regimens assessed by a summary of adverse events and clinical laboratory assessments
3) Quality of life (QoL)
Exploratory
1) Determination of plasma YKL-40 and IL-6 and circulating tumor KRAS mutations in plasma and urine
|
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
12 month after last patient were included in the trial |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | Yes |
E.6.13.1 | Other scope of the trial description |
Correlation between biomarkers in blood (e.g. Ca-19-9, IL-6, CRP and YKL- 40) and clinical endpoints. |
|
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
The trial involves single site in the Member State concerned
| Yes |
E.8.4 | The trial involves multiple sites in the Member State concerned | No |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 5 |
E.8.9.1 | In the Member State concerned months | 0 |
E.8.9.1 | In the Member State concerned days | 0 |
E.8.9.2 | In all countries concerned by the trial years | 0 |
E.8.9.2 | In all countries concerned by the trial months | 0 |
E.8.9.2 | In all countries concerned by the trial days | 0 |